MSI2 and myeloid leukemia: Recently, the RNA-binding protein Musashi 2 (MSI2), which is a potent oncogene in myeloid leukemia and gastrointestinal malignancies, was found to enhance CSC properties, including self-renewal, drug resistance and tumorigenicity, by activating LIN28 in a mouse xenograft model of HCC14.